Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
Publishing timestamp: 2023-11-02 12:42:51
Summary
Eli Lilly reported third-quarter revenue and adjusted earnings that exceeded expectations, driven by strong demand for its diabetes drug Mounjaro. However, the company lowered its full-year profit guidance due to charges related to recent acquisitions. The stock rose more than 7% in morning trading.
Sentiment: MIXED
Keywords: health care industry, breaking news: earnings, eli lilly and co, business news, breaking news, business, biotech and pharmaceuticals, weight management, biotechnology, earnings, novo nordisk a/s, pharmaceuticals,
Source: https://www.cnbc.com/2023/11/02/eli-lilly-lly-q3-earnings-report-2023.html